StockGlow

Ascelia Pharma AB (publ) (ACE.ST)

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden.

0.53+0.05%Healthcare
Compare ACE.ST with
StockGlow Score
20
Leaning Bearish
BearishBullish
1 year ago-88.6%

The outlook

Ascelia Pharma AB (publ) currently reads as leaning bearish based on below its 50- & 200-day averages, 2% of the way from its 52-week low to high, avg target +438% vs current price. This is a snapshot of current market data, not a forecast.

What’s behind the score

Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +438% vs current price

Analyst price target

~12-month · 3 analysts
2.87average target+437.8% vs now
Now 0.53
Low 1.20High 3.70

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$71.2M
52-wk high
5.23
52-wk low
0.46
50-day avg
2.02
200-day avg
2.75
Trailing P/E
—

Similar stocks

HNSA.STHansa Biopharma AB (publ)$34.40+0.29%SANION.STSaniona AB (publ)$14.23+1.79%ATORX.STAlligator Bioscience AB (publ)$0.04+4.14%BINV.STBioInvent International AB (publ)$22.95-1.08%CANTA.STCantargia AB (publ)$1.82+0.33%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy